Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Skin Neoplasms | 75 | 2024 | 5812 | 6.910 |
Why?
|
Melanoma | 41 | 2022 | 5697 | 4.360 |
Why?
|
Proto-Oncogene Proteins B-raf | 18 | 2018 | 2057 | 2.590 |
Why?
|
Sweat Gland Neoplasms | 7 | 2015 | 116 | 2.460 |
Why?
|
Skin Diseases | 12 | 2020 | 1094 | 2.380 |
Why?
|
Immunohistochemistry | 32 | 2020 | 11069 | 2.170 |
Why?
|
Neoplasms, Adnexal and Skin Appendage | 5 | 2012 | 27 | 1.800 |
Why?
|
Carcinoma, Squamous Cell | 13 | 2020 | 4020 | 1.630 |
Why?
|
Keratoacanthoma | 3 | 2017 | 33 | 1.590 |
Why?
|
Keratin-15 | 6 | 2017 | 22 | 1.550 |
Why?
|
Carcinoma, Basal Cell | 7 | 2020 | 557 | 1.470 |
Why?
|
Skin | 12 | 2023 | 4473 | 1.350 |
Why?
|
Intermediate Filament Proteins | 6 | 2012 | 262 | 1.310 |
Why?
|
Carcinoma in Situ | 4 | 2022 | 791 | 1.160 |
Why?
|
Nevus | 5 | 2012 | 205 | 1.100 |
Why?
|
Mycosis Fungoides | 2 | 2020 | 170 | 1.080 |
Why?
|
Neoplasm Invasiveness | 10 | 2017 | 3593 | 1.040 |
Why?
|
Elastic Tissue | 4 | 2020 | 66 | 1.030 |
Why?
|
Eccrine Glands | 3 | 2012 | 52 | 1.020 |
Why?
|
Receptors, Nerve Growth Factor | 3 | 2015 | 198 | 1.000 |
Why?
|
Neurofibromin 1 | 2 | 2017 | 190 | 0.970 |
Why?
|
Telomerase | 3 | 2020 | 744 | 0.920 |
Why?
|
Muir-Torre Syndrome | 2 | 2017 | 12 | 0.910 |
Why?
|
Alopecia | 4 | 2017 | 412 | 0.880 |
Why?
|
Nevus, Pigmented | 4 | 2015 | 222 | 0.870 |
Why?
|
Insulin-Like Growth Factor Binding Proteins | 5 | 2010 | 208 | 0.860 |
Why?
|
Neoplastic Stem Cells | 4 | 2012 | 1350 | 0.840 |
Why?
|
Peripheral Nerves | 3 | 2015 | 479 | 0.820 |
Why?
|
Eccrine Porocarcinoma | 2 | 2013 | 18 | 0.810 |
Why?
|
Histiocytoma, Benign Fibrous | 3 | 2013 | 64 | 0.810 |
Why?
|
Hemangioma | 2 | 2020 | 727 | 0.790 |
Why?
|
Biopsy | 19 | 2020 | 6762 | 0.770 |
Why?
|
Epidermis | 2 | 2017 | 527 | 0.750 |
Why?
|
Epithelial-Mesenchymal Transition | 2 | 2016 | 737 | 0.740 |
Why?
|
Dermatofibrosarcoma | 3 | 2013 | 48 | 0.720 |
Why?
|
Mutation | 14 | 2020 | 30016 | 0.680 |
Why?
|
Nerve Tissue Proteins | 9 | 2015 | 4408 | 0.670 |
Why?
|
Granuloma | 2 | 2019 | 328 | 0.660 |
Why?
|
Testis | 1 | 2023 | 792 | 0.650 |
Why?
|
Cicatrix | 3 | 2017 | 785 | 0.650 |
Why?
|
Apolipoproteins D | 2 | 2009 | 14 | 0.640 |
Why?
|
Drug Eruptions | 3 | 2015 | 335 | 0.640 |
Why?
|
Sebaceous Gland Neoplasms | 2 | 2009 | 40 | 0.610 |
Why?
|
Skin Pigmentation | 1 | 2020 | 277 | 0.610 |
Why?
|
Hyperpigmentation | 2 | 2020 | 116 | 0.610 |
Why?
|
Diagnosis, Differential | 21 | 2020 | 12966 | 0.610 |
Why?
|
GTP Phosphohydrolases | 3 | 2018 | 517 | 0.600 |
Why?
|
Psoriasis | 2 | 2019 | 944 | 0.600 |
Why?
|
Histiocytosis, Sinus | 1 | 2017 | 44 | 0.580 |
Why?
|
Carcinoma, Merkel Cell | 2 | 2019 | 328 | 0.570 |
Why?
|
Exanthema | 1 | 2022 | 503 | 0.560 |
Why?
|
Malpractice | 1 | 2022 | 556 | 0.560 |
Why?
|
Fibroma | 2 | 2009 | 190 | 0.560 |
Why?
|
Humans | 127 | 2024 | 760617 | 0.550 |
Why?
|
Genes, Neurofibromatosis 1 | 1 | 2017 | 74 | 0.550 |
Why?
|
Pathology | 2 | 2011 | 269 | 0.540 |
Why?
|
Hypopigmentation | 2 | 2020 | 43 | 0.530 |
Why?
|
Lymphocytes, Tumor-Infiltrating | 2 | 2024 | 1088 | 0.520 |
Why?
|
Monoclonal Gammopathy of Undetermined Significance | 1 | 2017 | 179 | 0.500 |
Why?
|
Keratosis | 1 | 2015 | 79 | 0.500 |
Why?
|
Dermatitis | 2 | 2014 | 202 | 0.490 |
Why?
|
Membrane Proteins | 7 | 2018 | 7847 | 0.490 |
Why?
|
Pseudoxanthoma Elasticum | 1 | 2015 | 14 | 0.490 |
Why?
|
Acrospiroma | 1 | 2015 | 11 | 0.490 |
Why?
|
Sarcoma | 3 | 2024 | 1800 | 0.490 |
Why?
|
Erythema Nodosum | 1 | 2014 | 32 | 0.480 |
Why?
|
Aged, 80 and over | 27 | 2024 | 58894 | 0.480 |
Why?
|
Molecular Diagnostic Techniques | 1 | 2019 | 610 | 0.470 |
Why?
|
Keratosis, Actinic | 2 | 2012 | 72 | 0.470 |
Why?
|
Proto-Oncogene Proteins c-kit | 3 | 2015 | 727 | 0.460 |
Why?
|
Tumor Escape | 1 | 2017 | 371 | 0.460 |
Why?
|
Hair Follicle | 3 | 2017 | 211 | 0.460 |
Why?
|
Receptor, trkA | 1 | 2015 | 159 | 0.460 |
Why?
|
Multiple Endocrine Neoplasia Type 2b | 1 | 2013 | 10 | 0.460 |
Why?
|
Hepatocyte Growth Factor | 1 | 2015 | 271 | 0.460 |
Why?
|
GTP-Binding Protein alpha Subunits | 2 | 2015 | 102 | 0.460 |
Why?
|
Precancerous Conditions | 2 | 2012 | 980 | 0.460 |
Why?
|
Cell Separation | 2 | 2018 | 1718 | 0.460 |
Why?
|
Veterans | 3 | 2023 | 2649 | 0.450 |
Why?
|
Sarcoidosis | 1 | 2019 | 521 | 0.450 |
Why?
|
bcl-2 Homologous Antagonist-Killer Protein | 1 | 2013 | 71 | 0.440 |
Why?
|
Military Personnel | 1 | 2023 | 1245 | 0.440 |
Why?
|
Loss of Heterozygosity | 1 | 2016 | 662 | 0.440 |
Why?
|
Carcinoma | 2 | 2016 | 2327 | 0.440 |
Why?
|
Neoplasms, Vascular Tissue | 1 | 2013 | 25 | 0.430 |
Why?
|
Cadherins | 2 | 2016 | 901 | 0.430 |
Why?
|
DNA Mutational Analysis | 7 | 2018 | 4110 | 0.420 |
Why?
|
Receptors, CXCR4 | 2 | 2014 | 727 | 0.420 |
Why?
|
Matrix Metalloproteinase 14 | 1 | 2012 | 60 | 0.410 |
Why?
|
Lymphoma, Large B-Cell, Diffuse | 1 | 2023 | 1405 | 0.410 |
Why?
|
Histiocytosis, Non-Langerhans-Cell | 1 | 2012 | 22 | 0.400 |
Why?
|
Levamisole | 1 | 2012 | 35 | 0.400 |
Why?
|
Aged | 38 | 2024 | 169042 | 0.400 |
Why?
|
Neoplasms, Fibrous Tissue | 1 | 2012 | 20 | 0.400 |
Why?
|
Chemokine CXCL12 | 1 | 2014 | 454 | 0.400 |
Why?
|
Scalp Dermatoses | 1 | 2012 | 44 | 0.400 |
Why?
|
Ecchymosis | 1 | 2012 | 32 | 0.400 |
Why?
|
Breast Diseases | 1 | 2015 | 443 | 0.400 |
Why?
|
Skin Diseases, Vascular | 1 | 2012 | 41 | 0.390 |
Why?
|
Proto-Oncogene Proteins c-met | 1 | 2015 | 571 | 0.380 |
Why?
|
Neoplasms, Complex and Mixed | 1 | 2011 | 35 | 0.380 |
Why?
|
Skin Physiological Phenomena | 1 | 2012 | 188 | 0.380 |
Why?
|
Dermis | 1 | 2013 | 202 | 0.380 |
Why?
|
Head and Neck Neoplasms | 4 | 2020 | 2894 | 0.380 |
Why?
|
SOXE Transcription Factors | 3 | 2020 | 73 | 0.370 |
Why?
|
Middle Aged | 41 | 2024 | 220584 | 0.370 |
Why?
|
Keratin-19 | 1 | 2010 | 33 | 0.360 |
Why?
|
Apocrine Glands | 1 | 2010 | 32 | 0.360 |
Why?
|
Diphosphonates | 1 | 2015 | 635 | 0.360 |
Why?
|
Microdissection | 1 | 2011 | 151 | 0.360 |
Why?
|
Gelatinases | 1 | 2010 | 88 | 0.360 |
Why?
|
Nevus, Blue | 1 | 2010 | 43 | 0.360 |
Why?
|
Adenocarcinoma, Clear Cell | 1 | 2012 | 217 | 0.360 |
Why?
|
Male | 52 | 2024 | 360358 | 0.360 |
Why?
|
Fibrosis | 2 | 2017 | 2045 | 0.350 |
Why?
|
Matrix Metalloproteinase 2 | 1 | 2012 | 459 | 0.350 |
Why?
|
Lymphatic Vessels | 1 | 2014 | 356 | 0.350 |
Why?
|
Microvessels | 1 | 2014 | 577 | 0.350 |
Why?
|
Sarcoma, Kaposi | 2 | 2013 | 374 | 0.350 |
Why?
|
Dysplastic Nevus Syndrome | 1 | 2010 | 61 | 0.340 |
Why?
|
Granular Cell Tumor | 1 | 2010 | 48 | 0.340 |
Why?
|
Hemangiosarcoma | 2 | 2013 | 215 | 0.340 |
Why?
|
Carcinoma, Mucoepidermoid | 1 | 2010 | 89 | 0.340 |
Why?
|
Matrix Metalloproteinases | 1 | 2012 | 391 | 0.340 |
Why?
|
Dermatology | 3 | 2011 | 918 | 0.340 |
Why?
|
Proto-Oncogene Proteins c-ret | 4 | 2016 | 225 | 0.340 |
Why?
|
Cell Transformation, Neoplastic | 2 | 2017 | 2821 | 0.340 |
Why?
|
Imidazoles | 1 | 2015 | 1175 | 0.330 |
Why?
|
Lymphoma, T-Cell | 1 | 2012 | 304 | 0.330 |
Why?
|
Neovascularization, Pathologic | 3 | 2014 | 2644 | 0.330 |
Why?
|
Colitis, Ulcerative | 2 | 2014 | 1921 | 0.330 |
Why?
|
Matrix Metalloproteinase 9 | 1 | 2012 | 632 | 0.330 |
Why?
|
Adenoma | 2 | 2012 | 2159 | 0.320 |
Why?
|
Female | 55 | 2019 | 392148 | 0.320 |
Why?
|
Antigens, CD34 | 2 | 2010 | 658 | 0.320 |
Why?
|
Darier Disease | 1 | 2008 | 13 | 0.320 |
Why?
|
ATP-Binding Cassette Transporters | 1 | 2012 | 563 | 0.320 |
Why?
|
Biopsy, Needle | 3 | 2019 | 1624 | 0.310 |
Why?
|
Stem Cells | 3 | 2011 | 3516 | 0.310 |
Why?
|
Nevus, Epithelioid and Spindle Cell | 1 | 2009 | 70 | 0.310 |
Why?
|
Bone Density Conservation Agents | 1 | 2015 | 794 | 0.300 |
Why?
|
Wound Healing | 1 | 2019 | 2802 | 0.300 |
Why?
|
Sebaceous Gland Diseases | 1 | 2007 | 5 | 0.300 |
Why?
|
Carcinoma, Skin Appendage | 1 | 2007 | 5 | 0.300 |
Why?
|
Predictive Value of Tests | 10 | 2020 | 15251 | 0.300 |
Why?
|
DNA-Binding Proteins | 4 | 2017 | 9586 | 0.300 |
Why?
|
Skin Diseases, Papulosquamous | 1 | 2007 | 17 | 0.300 |
Why?
|
Pathology, Molecular | 1 | 2011 | 329 | 0.290 |
Why?
|
Proto-Oncogene Proteins c-myc | 1 | 2013 | 988 | 0.290 |
Why?
|
Prognosis | 11 | 2020 | 29600 | 0.290 |
Why?
|
Keratolytic Agents | 2 | 2017 | 34 | 0.290 |
Why?
|
Hemangioendothelioma, Epithelioid | 1 | 2008 | 54 | 0.280 |
Why?
|
Carcinoma, Ductal | 1 | 2007 | 97 | 0.280 |
Why?
|
Cocaine | 1 | 2012 | 958 | 0.270 |
Why?
|
Adjuvants, Immunologic | 1 | 2012 | 990 | 0.270 |
Why?
|
Lasers | 1 | 2011 | 952 | 0.270 |
Why?
|
Salivary Gland Neoplasms | 1 | 2010 | 304 | 0.270 |
Why?
|
Neurofibromatoses | 1 | 2010 | 299 | 0.270 |
Why?
|
Nuclear Proteins | 2 | 2019 | 5789 | 0.270 |
Why?
|
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2010 | 382 | 0.270 |
Why?
|
Immunocompromised Host | 2 | 2011 | 858 | 0.260 |
Why?
|
Phenotype | 6 | 2018 | 16571 | 0.260 |
Why?
|
Tumor Microenvironment | 2 | 2017 | 3868 | 0.260 |
Why?
|
Thigh | 2 | 2017 | 240 | 0.260 |
Why?
|
Antibodies, Monoclonal | 3 | 2012 | 9172 | 0.260 |
Why?
|
Mast Cells | 1 | 2013 | 1392 | 0.260 |
Why?
|
Adenoma, Oxyphilic | 1 | 2007 | 148 | 0.250 |
Why?
|
Antigens, CD | 3 | 2016 | 3998 | 0.250 |
Why?
|
Hamartoma | 1 | 2007 | 235 | 0.250 |
Why?
|
Glioblastoma | 1 | 2020 | 3481 | 0.250 |
Why?
|
Neurofibromatosis 1 | 1 | 2010 | 560 | 0.250 |
Why?
|
Neoplastic Syndromes, Hereditary | 1 | 2007 | 245 | 0.250 |
Why?
|
Serine Endopeptidases | 1 | 2010 | 1022 | 0.250 |
Why?
|
Neoplasm Recurrence, Local | 3 | 2020 | 9277 | 0.240 |
Why?
|
Adult | 31 | 2019 | 220969 | 0.240 |
Why?
|
Mohs Surgery | 2 | 2017 | 222 | 0.240 |
Why?
|
Sequence Analysis, DNA | 2 | 2015 | 4739 | 0.240 |
Why?
|
Dermatomyositis | 1 | 2007 | 258 | 0.230 |
Why?
|
Myelodysplastic Syndromes | 1 | 2014 | 1394 | 0.230 |
Why?
|
Antigens, Neoplasm | 1 | 2012 | 1985 | 0.230 |
Why?
|
Chi-Square Distribution | 3 | 2016 | 3410 | 0.220 |
Why?
|
Vasculitis | 1 | 2008 | 522 | 0.220 |
Why?
|
Fibroblasts | 3 | 2010 | 4137 | 0.220 |
Why?
|
Leukemia, Myeloid, Acute | 1 | 2019 | 3612 | 0.220 |
Why?
|
Drug Resistance, Neoplasm | 2 | 2015 | 5304 | 0.220 |
Why?
|
Family Health | 1 | 2008 | 1253 | 0.220 |
Why?
|
Lymphangitis | 1 | 2023 | 15 | 0.220 |
Why?
|
Mycobacterium marinum | 1 | 2023 | 29 | 0.210 |
Why?
|
CD8-Positive T-Lymphocytes | 1 | 2017 | 4571 | 0.210 |
Why?
|
Thyroid Neoplasms | 1 | 2016 | 2332 | 0.210 |
Why?
|
Education, Medical, Continuing | 1 | 2008 | 823 | 0.210 |
Why?
|
Adenocarcinoma | 3 | 2014 | 6340 | 0.210 |
Why?
|
Acantholysis | 1 | 2022 | 11 | 0.200 |
Why?
|
Tattooing | 1 | 2002 | 57 | 0.200 |
Why?
|
Sunlight | 2 | 2014 | 337 | 0.200 |
Why?
|
Ki-67 Antigen | 2 | 2016 | 627 | 0.200 |
Why?
|
GTP-Binding Protein alpha Subunits, Gq-G11 | 2 | 2015 | 147 | 0.200 |
Why?
|
Scleroderma, Localized | 1 | 2002 | 87 | 0.190 |
Why?
|
Ear, External | 1 | 2002 | 165 | 0.190 |
Why?
|
Ichthyosis | 1 | 2022 | 59 | 0.190 |
Why?
|
Cell Adhesion Molecules | 1 | 2008 | 1602 | 0.190 |
Why?
|
Adolescent | 14 | 2016 | 88234 | 0.190 |
Why?
|
Arthroplasty, Replacement, Knee | 1 | 2012 | 1393 | 0.190 |
Why?
|
Genetic Testing | 2 | 2020 | 3533 | 0.190 |
Why?
|
Necrosis | 2 | 2019 | 1610 | 0.190 |
Why?
|
Photochemotherapy | 2 | 2017 | 823 | 0.180 |
Why?
|
Young Adult | 11 | 2016 | 59179 | 0.180 |
Why?
|
Incidence | 1 | 2019 | 21337 | 0.180 |
Why?
|
Acquired Immunodeficiency Syndrome | 1 | 2009 | 2197 | 0.180 |
Why?
|
Apoptosis | 3 | 2013 | 9476 | 0.180 |
Why?
|
Melanocytes | 4 | 2011 | 509 | 0.180 |
Why?
|
Telangiectasis | 1 | 2020 | 78 | 0.170 |
Why?
|
Skin Abnormalities | 1 | 2020 | 59 | 0.170 |
Why?
|
S100 Proteins | 1 | 2020 | 217 | 0.170 |
Why?
|
Amyloidosis | 2 | 2007 | 815 | 0.170 |
Why?
|
Diagnostic Errors | 1 | 2007 | 1265 | 0.170 |
Why?
|
Dermoscopy | 1 | 2020 | 66 | 0.170 |
Why?
|
Organ Transplantation | 1 | 2009 | 1157 | 0.170 |
Why?
|
Membrane Glycoproteins | 1 | 2010 | 3688 | 0.160 |
Why?
|
Brain Neoplasms | 1 | 2020 | 9026 | 0.160 |
Why?
|
Esophageal Neoplasms | 1 | 2009 | 1653 | 0.160 |
Why?
|
Sensitivity and Specificity | 5 | 2017 | 14648 | 0.160 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 1 | 2017 | 5319 | 0.160 |
Why?
|
Skin Ulcer | 1 | 2019 | 130 | 0.150 |
Why?
|
Quality Assurance, Health Care | 1 | 2008 | 2164 | 0.150 |
Why?
|
Retrospective Studies | 10 | 2022 | 80566 | 0.150 |
Why?
|
Cytoplasm | 2 | 2012 | 1503 | 0.150 |
Why?
|
Cancer Care Facilities | 1 | 2020 | 421 | 0.150 |
Why?
|
Histological Techniques | 1 | 2018 | 194 | 0.140 |
Why?
|
Neoplasm Proteins | 1 | 2009 | 3607 | 0.140 |
Why?
|
Antibodies, Monoclonal, Murine-Derived | 2 | 2010 | 693 | 0.140 |
Why?
|
Gene Expression Regulation, Neoplastic | 6 | 2016 | 8542 | 0.140 |
Why?
|
Methicillin-Resistant Staphylococcus aureus | 1 | 2023 | 697 | 0.130 |
Why?
|
Prednisone | 2 | 2019 | 1562 | 0.130 |
Why?
|
Neoplasm Staging | 3 | 2023 | 11116 | 0.130 |
Why?
|
New England | 1 | 2019 | 1051 | 0.130 |
Why?
|
Stromal Cells | 2 | 2012 | 1329 | 0.130 |
Why?
|
Leg | 2 | 2019 | 1087 | 0.130 |
Why?
|
Acanthosis Nigricans | 1 | 2015 | 47 | 0.130 |
Why?
|
Signal Transduction | 6 | 2017 | 23416 | 0.130 |
Why?
|
Kidney Transplantation | 1 | 2011 | 4236 | 0.130 |
Why?
|
Autoimmune Diseases | 1 | 2008 | 2238 | 0.130 |
Why?
|
Syphilis, Cutaneous | 1 | 2015 | 6 | 0.130 |
Why?
|
Penicillin G Benzathine | 1 | 2015 | 25 | 0.120 |
Why?
|
Cell Lineage | 2 | 2017 | 2554 | 0.120 |
Why?
|
Atrophy | 1 | 2020 | 1631 | 0.120 |
Why?
|
Ochronosis | 1 | 2014 | 7 | 0.120 |
Why?
|
Polymorphism, Genetic | 3 | 2016 | 4242 | 0.120 |
Why?
|
Lung Neoplasms | 2 | 2017 | 13382 | 0.120 |
Why?
|
Germ-Line Mutation | 2 | 2017 | 1852 | 0.120 |
Why?
|
Molecular Targeted Therapy | 2 | 2017 | 2812 | 0.120 |
Why?
|
Preleukemia | 1 | 2014 | 34 | 0.120 |
Why?
|
Rickettsia rickettsii | 1 | 2014 | 5 | 0.120 |
Why?
|
Rocky Mountain Spotted Fever | 1 | 2014 | 19 | 0.120 |
Why?
|
Scalp | 2 | 2008 | 389 | 0.120 |
Why?
|
Facial Dermatoses | 1 | 2014 | 86 | 0.110 |
Why?
|
United States Department of Veterans Affairs | 1 | 2019 | 928 | 0.110 |
Why?
|
Skin Transplantation | 1 | 2019 | 1083 | 0.110 |
Why?
|
Polymerase Chain Reaction | 2 | 2014 | 6074 | 0.110 |
Why?
|
Penis | 1 | 2015 | 210 | 0.110 |
Why?
|
Nevirapine | 1 | 2015 | 273 | 0.110 |
Why?
|
Boston | 3 | 2011 | 9313 | 0.110 |
Why?
|
Sunscreening Agents | 1 | 2014 | 139 | 0.110 |
Why?
|
Extracellular Matrix | 2 | 2012 | 1718 | 0.110 |
Why?
|
Nipples | 1 | 2015 | 229 | 0.110 |
Why?
|
Lymphangiogenesis | 1 | 2014 | 171 | 0.110 |
Why?
|
History, 19th Century | 1 | 2015 | 718 | 0.110 |
Why?
|
Skin Diseases, Infectious | 1 | 2013 | 76 | 0.100 |
Why?
|
Osteoporosis, Postmenopausal | 1 | 2015 | 396 | 0.100 |
Why?
|
Clinical Competence | 1 | 2008 | 4789 | 0.100 |
Why?
|
Oncogene Proteins, Viral | 1 | 2013 | 340 | 0.100 |
Why?
|
Cell Count | 2 | 2013 | 1835 | 0.100 |
Why?
|
Vascular Endothelial Growth Factor Receptor-2 | 1 | 2014 | 546 | 0.100 |
Why?
|
Lichenoid Eruptions | 1 | 2011 | 13 | 0.100 |
Why?
|
Anti-Bacterial Agents | 5 | 2023 | 7402 | 0.100 |
Why?
|
Neuropilin-2 | 1 | 2011 | 55 | 0.100 |
Why?
|
Clusterin | 1 | 2011 | 71 | 0.100 |
Why?
|
Health Behavior | 1 | 2023 | 2643 | 0.090 |
Why?
|
Vaccination | 2 | 2022 | 3370 | 0.090 |
Why?
|
Bowen's Disease | 1 | 2010 | 13 | 0.090 |
Why?
|
Metaplasia | 1 | 2012 | 322 | 0.090 |
Why?
|
Carcinoma, Papillary | 1 | 2016 | 785 | 0.090 |
Why?
|
Cell Proliferation | 6 | 2014 | 10432 | 0.090 |
Why?
|
Cross-Sectional Studies | 4 | 2016 | 26049 | 0.090 |
Why?
|
Infusions, Intravenous | 1 | 2015 | 2214 | 0.090 |
Why?
|
Drug Contamination | 1 | 2012 | 151 | 0.090 |
Why?
|
Immunoenzyme Techniques | 2 | 2011 | 1703 | 0.090 |
Why?
|
Antigens, Differentiation, Myelomonocytic | 1 | 2012 | 283 | 0.090 |
Why?
|
Carcinoembryonic Antigen | 1 | 2012 | 335 | 0.090 |
Why?
|
Promoter Regions, Genetic | 2 | 2020 | 5780 | 0.090 |
Why?
|
Antigens, CD7 | 1 | 2010 | 29 | 0.090 |
Why?
|
Deoxycytidine | 1 | 2015 | 878 | 0.090 |
Why?
|
Keratins | 1 | 2012 | 498 | 0.090 |
Why?
|
Sequence Analysis | 1 | 2011 | 240 | 0.090 |
Why?
|
Genetic Predisposition to Disease | 3 | 2018 | 17878 | 0.080 |
Why?
|
MAP Kinase Signaling System | 2 | 2015 | 1483 | 0.080 |
Why?
|
Proteins | 2 | 2018 | 6030 | 0.080 |
Why?
|
Tissue Fixation | 1 | 2011 | 241 | 0.080 |
Why?
|
Postoperative Complications | 1 | 2012 | 15612 | 0.080 |
Why?
|
History, 21st Century | 1 | 2015 | 1565 | 0.080 |
Why?
|
Microphthalmia-Associated Transcription Factor | 1 | 2011 | 259 | 0.080 |
Why?
|
Hypothyroidism | 1 | 2014 | 667 | 0.080 |
Why?
|
Adenine | 1 | 2015 | 985 | 0.080 |
Why?
|
Receptors, Notch | 1 | 2014 | 743 | 0.080 |
Why?
|
Colectomy | 1 | 2014 | 686 | 0.080 |
Why?
|
Skin Diseases, Vesiculobullous | 1 | 2009 | 85 | 0.080 |
Why?
|
Receptors, Progesterone | 1 | 2013 | 1129 | 0.080 |
Why?
|
Genomics | 2 | 2018 | 5822 | 0.080 |
Why?
|
Nerve Sheath Neoplasms | 1 | 2010 | 170 | 0.080 |
Why?
|
Cocaine-Related Disorders | 1 | 2012 | 461 | 0.080 |
Why?
|
Tumor Suppressor Proteins | 4 | 2014 | 2801 | 0.080 |
Why?
|
Algorithms | 1 | 2009 | 14018 | 0.080 |
Why?
|
Treatment Failure | 1 | 2015 | 2635 | 0.080 |
Why?
|
Down-Regulation | 1 | 2016 | 2915 | 0.080 |
Why?
|
Nucleic Acids | 1 | 2011 | 187 | 0.080 |
Why?
|
Base Pair Mismatch | 1 | 2007 | 92 | 0.070 |
Why?
|
Sarcoplasmic Reticulum Calcium-Transporting ATPases | 1 | 2008 | 128 | 0.070 |
Why?
|
Panniculitis | 1 | 2008 | 45 | 0.070 |
Why?
|
Fusarium | 1 | 2008 | 51 | 0.070 |
Why?
|
RNA | 1 | 2018 | 2713 | 0.070 |
Why?
|
Health Education | 1 | 2014 | 1049 | 0.070 |
Why?
|
Dermatomycoses | 1 | 2008 | 48 | 0.070 |
Why?
|
Keratosis, Seborrheic | 1 | 2007 | 27 | 0.070 |
Why?
|
Structure-Activity Relationship | 1 | 2013 | 3074 | 0.070 |
Why?
|
History, 20th Century | 1 | 2015 | 2764 | 0.070 |
Why?
|
Giant Cell Tumors | 1 | 2007 | 89 | 0.070 |
Why?
|
Herpesvirus 8, Human | 1 | 2009 | 255 | 0.070 |
Why?
|
Combined Modality Therapy | 1 | 2019 | 8516 | 0.070 |
Why?
|
Embryonic Development | 1 | 2012 | 721 | 0.070 |
Why?
|
Artificial Intelligence | 1 | 2022 | 2574 | 0.070 |
Why?
|
Subcutaneous Tissue | 1 | 2008 | 132 | 0.070 |
Why?
|
MutS Homolog 2 Protein | 1 | 2007 | 197 | 0.070 |
Why?
|
Genotype | 2 | 2012 | 12978 | 0.070 |
Why?
|
Disease Progression | 3 | 2014 | 13495 | 0.070 |
Why?
|
In Situ Hybridization, Fluorescence | 1 | 2013 | 2509 | 0.070 |
Why?
|
Finger Joint | 1 | 2007 | 108 | 0.070 |
Why?
|
Recurrence | 1 | 2019 | 8426 | 0.070 |
Why?
|
Neuroectodermal Tumors, Primitive | 1 | 2008 | 136 | 0.070 |
Why?
|
Carcinoma, Verrucous | 1 | 2006 | 27 | 0.070 |
Why?
|
Treatment Outcome | 5 | 2020 | 64568 | 0.070 |
Why?
|
Lymphatic Metastasis | 1 | 2014 | 2913 | 0.070 |
Why?
|
Neoplasm, Residual | 1 | 2012 | 1008 | 0.070 |
Why?
|
Endopeptidases | 1 | 2010 | 774 | 0.070 |
Why?
|
Enzyme Activation | 1 | 2012 | 3591 | 0.070 |
Why?
|
Epidermal Cyst | 1 | 2007 | 64 | 0.070 |
Why?
|
Time Factors | 3 | 2019 | 39913 | 0.070 |
Why?
|
DNA, Neoplasm | 1 | 2012 | 1743 | 0.070 |
Why?
|
Extremities | 1 | 2012 | 867 | 0.070 |
Why?
|
Reproducibility of Results | 2 | 2019 | 20074 | 0.070 |
Why?
|
Herpesvirus 4, Human | 1 | 2012 | 1077 | 0.070 |
Why?
|
Fever | 1 | 2014 | 1618 | 0.070 |
Why?
|
Specialty Boards | 1 | 2008 | 235 | 0.070 |
Why?
|
Immunoglobulin A | 1 | 2009 | 978 | 0.070 |
Why?
|
Ciprofloxacin | 1 | 2008 | 312 | 0.070 |
Why?
|
Tumor Suppressor Protein p53 | 1 | 2016 | 2917 | 0.060 |
Why?
|
Cosmetic Techniques | 1 | 2008 | 148 | 0.060 |
Why?
|
Protein-Tyrosine Kinases | 1 | 2015 | 2425 | 0.060 |
Why?
|
Epstein-Barr Virus Infections | 1 | 2012 | 612 | 0.060 |
Why?
|
Neoplasms, Multiple Primary | 1 | 2009 | 592 | 0.060 |
Why?
|
Receptors, Estrogen | 1 | 2013 | 2208 | 0.060 |
Why?
|
Absorbable Implants | 1 | 2008 | 338 | 0.060 |
Why?
|
Microsatellite Repeats | 1 | 2007 | 783 | 0.060 |
Why?
|
Point Mutation | 1 | 2010 | 1595 | 0.060 |
Why?
|
Cerebellar Neoplasms | 1 | 2010 | 586 | 0.060 |
Why?
|
Protein Conformation | 1 | 2013 | 3965 | 0.060 |
Why?
|
Opportunistic Infections | 1 | 2008 | 376 | 0.060 |
Why?
|
Adrenal Gland Neoplasms | 1 | 2010 | 732 | 0.060 |
Why?
|
Certification | 1 | 2008 | 418 | 0.060 |
Why?
|
DNA Mismatch Repair | 1 | 2007 | 428 | 0.060 |
Why?
|
Fatal Outcome | 1 | 2009 | 1835 | 0.060 |
Why?
|
Muscle Weakness | 1 | 2007 | 412 | 0.060 |
Why?
|
Neoplasm Metastasis | 1 | 2015 | 4910 | 0.060 |
Why?
|
beta Catenin | 1 | 2009 | 1039 | 0.060 |
Why?
|
United States | 5 | 2021 | 72272 | 0.060 |
Why?
|
DNA | 1 | 2018 | 7196 | 0.060 |
Why?
|
Analysis of Variance | 1 | 2012 | 6224 | 0.060 |
Why?
|
Basic Helix-Loop-Helix Transcription Factors | 1 | 2010 | 1133 | 0.060 |
Why?
|
Face | 1 | 2010 | 1026 | 0.060 |
Why?
|
Epitopes | 1 | 2010 | 2501 | 0.060 |
Why?
|
Odds Ratio | 1 | 2016 | 9643 | 0.050 |
Why?
|
RNA, Viral | 1 | 2012 | 2838 | 0.050 |
Why?
|
Folliculitis | 1 | 2003 | 25 | 0.050 |
Why?
|
Immunophenotyping | 1 | 2008 | 1865 | 0.050 |
Why?
|
Disease-Free Survival | 1 | 2013 | 6807 | 0.050 |
Why?
|
Specialization | 1 | 2008 | 778 | 0.050 |
Why?
|
Severity of Illness Index | 2 | 2019 | 15828 | 0.050 |
Why?
|
Proto-Oncogene Proteins | 2 | 2013 | 4512 | 0.050 |
Why?
|
Registries | 1 | 2019 | 8207 | 0.050 |
Why?
|
Congo Red | 1 | 2002 | 48 | 0.050 |
Why?
|
Repressor Proteins | 1 | 2013 | 2985 | 0.050 |
Why?
|
Antineoplastic Agents | 2 | 2017 | 13635 | 0.050 |
Why?
|
Linear Models | 1 | 2012 | 5866 | 0.050 |
Why?
|
Multivariate Analysis | 1 | 2016 | 12043 | 0.050 |
Why?
|
Communicable Diseases | 1 | 2011 | 871 | 0.050 |
Why?
|
Influenza Vaccines | 1 | 2009 | 767 | 0.050 |
Why?
|
Survival Rate | 2 | 2013 | 12719 | 0.050 |
Why?
|
Papillomavirus Infections | 1 | 2013 | 1611 | 0.050 |
Why?
|
Immunotherapy | 1 | 2017 | 4642 | 0.050 |
Why?
|
Syndrome | 1 | 2007 | 3268 | 0.050 |
Why?
|
Logistic Models | 1 | 2016 | 13245 | 0.050 |
Why?
|
Surgery, Plastic | 1 | 2008 | 641 | 0.050 |
Why?
|
Proteome | 1 | 2011 | 1857 | 0.050 |
Why?
|
Pedigree | 1 | 2008 | 4539 | 0.040 |
Why?
|
Infant | 2 | 2016 | 36152 | 0.040 |
Why?
|
Child | 3 | 2016 | 80079 | 0.040 |
Why?
|
Regression Analysis | 1 | 2010 | 6338 | 0.040 |
Why?
|
Trans-Activators | 1 | 2010 | 2852 | 0.040 |
Why?
|
Organizations, Nonprofit | 1 | 2020 | 105 | 0.040 |
Why?
|
Child, Preschool | 2 | 2016 | 42188 | 0.040 |
Why?
|
Coloring Agents | 1 | 2002 | 562 | 0.040 |
Why?
|
Medicine | 1 | 2008 | 942 | 0.040 |
Why?
|
RNA, Messenger | 1 | 2014 | 12758 | 0.040 |
Why?
|
Follow-Up Studies | 2 | 2019 | 39063 | 0.040 |
Why?
|
Comorbidity | 1 | 2014 | 10505 | 0.040 |
Why?
|
Biocompatible Materials | 1 | 2008 | 1683 | 0.040 |
Why?
|
Single-Cell Analysis | 1 | 2011 | 2447 | 0.040 |
Why?
|
Abscess | 1 | 2003 | 606 | 0.040 |
Why?
|
Case-Control Studies | 1 | 2017 | 22148 | 0.040 |
Why?
|
Receptor, erbB-2 | 1 | 2009 | 2553 | 0.040 |
Why?
|
Staining and Labeling | 1 | 2002 | 1081 | 0.040 |
Why?
|
MicroRNAs | 1 | 2014 | 3805 | 0.040 |
Why?
|
Amyloid | 1 | 2002 | 841 | 0.040 |
Why?
|
Neoplasms | 3 | 2011 | 22131 | 0.040 |
Why?
|
Proteomics | 1 | 2011 | 3836 | 0.040 |
Why?
|
Adaptor Proteins, Signal Transducing | 1 | 2007 | 2895 | 0.040 |
Why?
|
Keratinocytes | 1 | 2021 | 790 | 0.030 |
Why?
|
Lymph Nodes | 1 | 2008 | 3461 | 0.030 |
Why?
|
Genes, p16 | 1 | 2016 | 160 | 0.030 |
Why?
|
Societies, Medical | 1 | 2008 | 3900 | 0.030 |
Why?
|
Animals | 5 | 2017 | 168201 | 0.030 |
Why?
|
Risk Assessment | 1 | 2017 | 23972 | 0.030 |
Why?
|
CD4-Positive T-Lymphocytes | 1 | 2008 | 4366 | 0.030 |
Why?
|
Mice, Nude | 2 | 2014 | 3605 | 0.030 |
Why?
|
Cell Differentiation | 1 | 2012 | 11514 | 0.030 |
Why?
|
Alkaptonuria | 1 | 2014 | 13 | 0.030 |
Why?
|
Lower Extremity | 1 | 2023 | 1200 | 0.030 |
Why?
|
Keratin-20 | 1 | 2014 | 31 | 0.030 |
Why?
|
Keratin-7 | 1 | 2014 | 55 | 0.030 |
Why?
|
Cell Line, Tumor | 4 | 2014 | 16967 | 0.030 |
Why?
|
Keratin-6 | 1 | 2014 | 17 | 0.030 |
Why?
|
Liver Neoplasms | 1 | 2010 | 4308 | 0.030 |
Why?
|
Transcription Factors | 2 | 2014 | 12116 | 0.030 |
Why?
|
Keratin-5 | 1 | 2014 | 45 | 0.030 |
Why?
|
Hypertension | 1 | 2014 | 8529 | 0.030 |
Why?
|
GATA3 Transcription Factor | 1 | 2014 | 154 | 0.030 |
Why?
|
Rad51 Recombinase | 1 | 2013 | 189 | 0.030 |
Why?
|
Basophils | 1 | 2014 | 407 | 0.030 |
Why?
|
Risk Factors | 1 | 2019 | 74115 | 0.020 |
Why?
|
Doxycycline | 1 | 2014 | 344 | 0.020 |
Why?
|
Eye | 1 | 2014 | 712 | 0.020 |
Why?
|
Myeloid-Lymphoid Leukemia Protein | 1 | 2013 | 305 | 0.020 |
Why?
|
Guideline Adherence | 1 | 2020 | 2218 | 0.020 |
Why?
|
Diabetes Mellitus, Type 2 | 1 | 2014 | 12142 | 0.020 |
Why?
|
Leg Dermatoses | 1 | 2009 | 20 | 0.020 |
Why?
|
Neck | 1 | 2014 | 734 | 0.020 |
Why?
|
Foot | 1 | 2014 | 575 | 0.020 |
Why?
|
Tissue Array Analysis | 1 | 2011 | 550 | 0.020 |
Why?
|
Hand Dermatoses | 1 | 2009 | 62 | 0.020 |
Why?
|
HT29 Cells | 1 | 2009 | 192 | 0.020 |
Why?
|
Recombinant Proteins | 2 | 2009 | 6520 | 0.020 |
Why?
|
Estrogen Receptor alpha | 1 | 2013 | 583 | 0.020 |
Why?
|
Cell Growth Processes | 1 | 2009 | 384 | 0.020 |
Why?
|
CD4 Lymphocyte Count | 1 | 2015 | 2567 | 0.020 |
Why?
|
Histone-Lysine N-Methyltransferase | 1 | 2013 | 682 | 0.020 |
Why?
|
DNA Breaks, Double-Stranded | 1 | 2013 | 612 | 0.020 |
Why?
|
HIV Infections | 1 | 2015 | 17337 | 0.020 |
Why?
|
Tumor Burden | 1 | 2014 | 1892 | 0.020 |
Why?
|
Coculture Techniques | 1 | 2011 | 1336 | 0.020 |
Why?
|
Tissue Transplantation | 1 | 2008 | 128 | 0.020 |
Why?
|
Back | 1 | 2007 | 64 | 0.020 |
Why?
|
Foreign-Body Reaction | 1 | 2008 | 157 | 0.020 |
Why?
|
Autocrine Communication | 1 | 2008 | 169 | 0.020 |
Why?
|
BRCA1 Protein | 1 | 2013 | 1149 | 0.020 |
Why?
|
Antiretroviral Therapy, Highly Active | 1 | 2015 | 1894 | 0.020 |
Why?
|
Collagen | 1 | 2014 | 2634 | 0.020 |
Why?
|
Paracrine Communication | 1 | 2008 | 277 | 0.020 |
Why?
|
Cohort Studies | 2 | 2021 | 41457 | 0.020 |
Why?
|
Pathology, Clinical | 1 | 2010 | 376 | 0.020 |
Why?
|
Transfection | 1 | 2014 | 5766 | 0.020 |
Why?
|
Kaplan-Meier Estimate | 1 | 2016 | 6474 | 0.020 |
Why?
|
ras Proteins | 1 | 2009 | 1054 | 0.010 |
Why?
|
RNA-Binding Proteins | 1 | 2013 | 1890 | 0.010 |
Why?
|
Neoplasm Transplantation | 1 | 2008 | 2010 | 0.010 |
Why?
|
Survival Analysis | 1 | 2016 | 10073 | 0.010 |
Why?
|
Amino Acid Substitution | 1 | 2008 | 1739 | 0.010 |
Why?
|
Practice Guidelines as Topic | 1 | 2020 | 7389 | 0.010 |
Why?
|
Chin | 1 | 2003 | 38 | 0.010 |
Why?
|
DNA Damage | 1 | 2013 | 2446 | 0.010 |
Why?
|
Gene Silencing | 1 | 2009 | 1503 | 0.010 |
Why?
|
Medicare | 1 | 2021 | 6765 | 0.010 |
Why?
|
Neutropenia | 1 | 2008 | 885 | 0.010 |
Why?
|
Prosthesis Failure | 1 | 2008 | 1204 | 0.010 |
Why?
|
Phosphorylation | 1 | 2013 | 8311 | 0.010 |
Why?
|
Cell Cycle Proteins | 1 | 2013 | 3447 | 0.010 |
Why?
|
Soft Tissue Neoplasms | 1 | 2010 | 1158 | 0.010 |
Why?
|
Xenograft Model Antitumor Assays | 1 | 2009 | 3599 | 0.010 |
Why?
|
Mice, Inbred BALB C | 1 | 2009 | 6188 | 0.010 |
Why?
|
Papillomaviridae | 1 | 2006 | 1117 | 0.010 |
Why?
|
Transplantation, Heterologous | 1 | 2008 | 2382 | 0.010 |
Why?
|
RNA Interference | 1 | 2008 | 2830 | 0.010 |
Why?
|
Cell Line | 1 | 2013 | 15576 | 0.010 |
Why?
|
Anti-HIV Agents | 1 | 2015 | 4524 | 0.010 |
Why?
|
Up-Regulation | 1 | 2008 | 4117 | 0.010 |
Why?
|
Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2008 | 1551 | 0.010 |
Why?
|
Influenza, Human | 1 | 2009 | 1518 | 0.010 |
Why?
|
Laser Therapy | 1 | 2003 | 1092 | 0.010 |
Why?
|
Epigenesis, Genetic | 1 | 2009 | 3794 | 0.010 |
Why?
|
Gene Expression Regulation | 1 | 2013 | 11874 | 0.010 |
Why?
|
Prospective Studies | 1 | 2016 | 54360 | 0.010 |
Why?
|
Mice | 2 | 2009 | 81368 | 0.010 |
Why?
|
Colorectal Neoplasms | 1 | 2009 | 6925 | 0.010 |
Why?
|